GlassScriptPhysician profile
Brandon A Conkling
NPI 1134273378
$9,853.24
in general payments reported to CMS, 2019-2025
34 companies · $1,852 in 2025
The $1,852 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $650 · 2021: $963 · 2022: $1,608 · 2023: $2,007 · 2024: $1,993 · 2025: $1,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,852.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,404.60 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,177.13 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,165.83 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Janssen Biotech, INC. | $832.32 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $618.93 | 2019-2025 | |
| Pfizer INC. | $583.23 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $309.80 | 2019-2024 | Rebyota |
| Celgene Corporation | $304.49 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $299.98 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $286.21 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $205.30 | 2024-2025 | Omvoh |
| Olympus America INC. | $202.52 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $180.51 | 2021-2024 | Dificid |
| Daiichi Sankyo INC. | $173.53 | 2019-2025 | Injectafer |
| Braintree Laboratories, INC. | $168.47 | 2020-2023 | Sutab |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $139.76 | 2022-2025 | |
| Ardelyx, INC. | $125.31 | 2023-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $101.91 | 2024-2025 | Iqirvo |
| Medtronic, INC. | $82.97 | 2022-2025 | Interstim |
| Intercept Pharmaceuticals, INC. | $77.68 | 2022-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $71.06 | 2020-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $67.94 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $67.18 | 2020-2023 | |
| Redhill Biopharma INC. | $45.93 | 2020 | |
| Qol Medical, LLC | $28.51 | 2025 | Sucraid |
| Novo Nordisk INC | $20.56 | 2025 | |
| Mylan Institutional INC. | $19.89 | 2023 | Hulio |
| Bayer Healthcare Pharmaceuticals INC. | $18.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.13 | 2025 | |
| Biocon Biologics INC | $15.54 | 2025 | Yesintek |
| Organon LLC | $15.14 | 2022 | |
| Sandoz INC. | $14.41 | 2023 | Hyrimoz |
| Amgen INC. | $11.24 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,097.44 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Conkling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.